Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
The present invention provides stable, ready-to-use injectable pharmaceutical compositions, comprising the combination of neostigmine, glycopyrrolate, a stabilizing amount of one or more aminopolycarboxylic acids, and a pharmaceutically acceptable liquid vehicle. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, ethylenediaminetetraacetic acid (EDTA) and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.
1. A stable ready-to-use injectable pharmaceutical composition for reversing the effects of non-depolarizing neuromuscular blocking agents in a patient in need thereof, comprising (i) about 1 mg/mL of neostigmine or a pharmaceutically acceptable salt, solvate or hydrate thereof, (ii) about 0.2 mg/mL of glycopyrrolate or a pharmaceutically acceptable salt, solvate or hydrate thereof, (iii) a pharmaceutically acceptable liquid vehicle, (iv) a tonicity modifier; and (v) a pH adjusting agent; wherein the level of Glycopyrrolate Impurity C in the composition is less than 1% when stored at 40° C. and 75% relative humidity for 3 months;
wherein the tonicity modifier is sodium chloride; and
wherein the pH adjusting agent is sodium hydroxide, hydrochloric acid or a mixture thereof.
2. The pharmaceutical composition according to claim 1 , wherein the composition is provided in a sealed container selected from the group consisting of ampoules, vials and pre-filled syringes.
3. The pharmaceutical composition according to claim 1 , wherein the composition is in the form of a solution, suspension, or emulsion.
4. The pharmaceutical composition according to claim 1 , wherein the composition is suitable for subcutaneous, intravenous or intramuscular administration.
5. The pharmaceutical composition according to claim 1 , comprising neostigmine methylsulfate and glycopyrronium bromide.
6. The pharmaceutical composition according to claim 1 , wherein the composition has a pH ranging from about 3.0 to about 4.0.
7. A stable ready-to-use injectable pharmaceutical composition comprising (i) about 1 mg/mL of neostigmine methylsulfate, (ii) about 0.2 mg/mL of glycopyrronium bromide, (iii) a pharmaceutically acceptable liquid vehicle; (iv) a tonicity modifier; and (v) q.s. of a pH adjusting agent, wherein the level of Glycopyrrolate Impurity C in the composition is less than 1%, when stored at 40° C. and 75% relative humidity for 3 months;
wherein the tonicity modifier is sodium chloride; and
wherein the pH adjusting agent is sodium hydroxide, hydrochloric acid or a mixture thereof.
8. The pharmaceutical composition according to claim 7 , wherein the composition is provided in a sealed container selected from the group consisting of ampoules, vials and pre-filled syringes.
9. The pharmaceutical composition according to claim 7 , wherein the composition has a pH ranging from about 3.0 to about 4.0.
10. A stable ready-to-use injectable pharmaceutical composition consisting of (i) about 1 mg/mL of neostigmine methylsulfate, (ii) about 0.2 mg/mL of glycopyrronium bromide, (iii) a pharmaceutically acceptable liquid vehicle; (iv) sodium chloride as tonicity modifier; and (v) sodium hydroxide, hydrochloric acid or mixture thereof as pH adjusting agent, wherein the level of Glycopyrrolate Impurity C in the composition is less than 1%, when stored at 40° C. and 75% relative humidity for 3 months.